Pfizer Inc.  

(Public, NYSE:PFE)   Watch this stock  
Find more results for PFE
29.26
-0.21 (-0.71%)
After Hours: 29.33 +0.07 (0.24%)
Jul 30, 7:52PM EDT  
NYSE real-time data - Disclaimer
Currency in USD
Range 29.03 - 29.54
52 week 27.76 - 32.96
Open 29.51
Vol / Avg. 33.99M/23.31M
Mkt cap 186.45B
P/E 18.34
Div/yield 0.26/3.55
EPS 1.60
Shares 6.37B
Beta 0.67
Inst. own 80%
Oct 27, 2014
Q3 2014 Pfizer Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Aug 6, 2014
Pfizer Inc at Piper Jaffray Heartland Summit (CEO's Perspective, Part 4) - 4:45PM EDT - Add to calendar
Aug 6, 2014
Pfizer Inc at Piper Jaffray Heartland Summit (CEO's Perspective, Part 1) - 11:30AM EDT - Add to calendar
Jul 29, 2014
Q2 2014 Pfizer Inc Earnings Call
Jul 29, 2014
Q2 2014 Pfizer Earnings Release
Jun 18, 2014
Pfizer Inc at Wells Fargo Healthcare Conference
Jun 11, 2014
Pfizer Inc at Goldman Sachs Healthcare Conference
May 19, 2014
Pfizer at UBS Global Healthcare Conference
May 6, 2014
Pfizer at Mizuho Securities USA Healthcare Corporate Access Day
May 5, 2014
Q1 2014 Pfizer Earnings Conference Call
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin 22.87% 22.12%
Operating margin 32.95% 31.32%
EBITD margin - 45.80%
Return on average assets - 6.38%
Return on average equity - 14.45%
Employees 77,700 -
CDP Score - 91 B

Address

235 E 42ND ST
NEW YORK, NY 10017
United States - Map
+1-212-5732323 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia

Description

Pfizer Inc. (Pfizer) is a research-based, global biopharmaceutical company. The Company manages its operations through five segments: Primary Care; Specialty Care and Oncology; Established Products and Emerging Markets; Animal Health, and Consumer Healthcare. The Company�s diversified global healthcare portfolio includes human and animal biologic and small molecule medicines and vaccines, as well as nutritional products and consumer healthcare products. Its Animal Health business unit discovers, develops and sells products for the prevention and treatment of diseases in livestock and companion animals. Primary Care operating segment includes revenues from human prescription pharmaceutical products primarily prescribed by primary-care physicians. In November 2012, the Company acquired NextWave Pharmaceuticals, Inc. On November 30, 2012, the Company completed the sale of its Nutrition business.

Officers and directors

Ian C. Read Chairman of the Board, Chief Executive Officer
Age: 60
Bio & Compensation  - Reuters
Frank A. D'Amelio Chief Financial Officer, Executive Vice President - Business Operations
Age: 56
Bio & Compensation  - Reuters
Albert Bourla Group President - Vaccines, Oncology and Consumer Healthcare Business
Age: 52
Bio & Compensation  - Reuters
Mikael Dolsten M.D., Ph.D. President - Worldwide Research and Development
Age: 55
Bio & Compensation  - Reuters
Geno J. Germano Group President - Global Innovative Pharma Business
Age: 53
Bio & Compensation  - Reuters
John D. Young Group President - Global Established Pharma Business
Age: 49
Bio & Compensation  - Reuters
Rady A. Johnson Executive Vice President, Chief Compliance and Risk Officer
Age: 52
Bio & Compensation  - Reuters
Douglas M. Lankler Executive Vice President, General Counsel
Age: 48
Bio & Compensation  - Reuters
Charles H. Hill III Executive Vice President - Worldwide Human Resources
Age: 58
Bio & Compensation  - Reuters
Freda C. Lewis-Hall M.D. Executive Vice President, Chief Medical Officer
Age: 59
Bio & Compensation  - Reuters